1-巯基-2-己醇 | 105551-87-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-巯基-2-己醇
• 英文名称: 1-Mercapto-2-hexanol
• 英文别名: 2-Hexanol, 1-mercapto-；1-sulfanylhexan-2-ol
• CAS: 105551-87-9
• 化学式: C₆H₁₄OS
• 分子量: 134.243
• InChiKey: XXIIBORLMZZLPO-UHFFFAOYSA-N

物化性质

• 沸点：
  201.3±23.0 °C(Predicted)
• 密度：
  0.962±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-巯基-2-己醇 在 lithium hydroxide 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 3.5h， 生成 <1S-<1α,2α(Z),3α,4α>>-7-<3-<<(2-Hydroxyhexyl)thio>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>-5-heptenoic acid
  参考文献：
  名称：

  9,11-Epoxy-9-homo-14-thiaprost-5-enoic acid derivatives: potent thromboxane A2 antagonists

  摘要：

  A novel bicyclic prostaglandin analogue, (1S)-[1 alpha,2 alpha(Z),3 alpha,4 alpha]-7-[3-[(hexylthio)methyl]-7- oxabicyclo [2.2.1]hept-2-yl]-5-heptenoic acid ((-)-10), and its cogeners were found to be potent antagonists at the TxA2 receptor. Compound (-)-10 was the only stereoisomer out of eight possible structures that was active. Thioether (-)-10 was 30-40-fold more potent than another TxA2 antagonist, BM 13.177, in inhibiting arachidonic acid (AA) induced aggregation of human platelet-rich plasma. Compound (-)-10 was effective (I50 = 0.5 +/- 0.4 microM) in inhibiting 9,11-azo-PGH2-induced (0.1 microgram/mL) contraction of guinea pig tracheal spirals. The bronchoconstriction in anesthetized guinea pigs induced by AA was also effectively antagonized by (-)-10 (1 mg/kg, iv); however, in this assay (-)-10 exhibited some direct agonist activity. Radioligand binding studies in washed (human) platelets revealed that (-)-10 is one of the most potent ligands for the PGH2/TxA2 receptor yet described (Kd = 1.6 +/- 0.4 nM).

  DOI：

  10.1021/jm00125a009
• 作为产物：
  描述：

  丁基环氧乙烷 在 二硫化碳 、 sodium hydrogensulfide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1-巯基-2-己醇
  参考文献：
  名称：

  Wu, Shao-Yong; Hirashima, Akinori; Takeya, Ryuko, Agricultural and Biological Chemistry, 1988, vol. 52, # 11, p. 2911 - 2918

  摘要：

  DOI：

文献信息

• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：Fujikura Hideki

  公开号：US20050080022A1

  公开（公告）日：2005-04-14

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃基氧基苄基苯衍生物：其中R1表示氢原子或羟基（较低烷基）基团；R2表示较低烷基基团、较低烷氧基团、较低烷基硫基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐。该化合物在人类SGLT2中具有优异的抑制活性，可用作预防或治疗糖尿病、肥胖等的药物，以及其中间体。
• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
  申请人：Fujikura Hideki

  公开号：US20050113315A1

  公开（公告）日：2005-05-26

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted(lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃氧基苯基苯乙烯衍生物： 其中，R1表示氢原子，羟基，取代或未取代的氨基，氨基甲酰基，取代或未取代的（较低烷基）基团，取代或未取代的（较低烷氧基）基团等；R2表示氢原子或较低烷基基团；R3表示取代或未取代的（较低烷基）基团，取代或未取代的（较低烷氧基）基团，取代或未取代的（较低烷硫基）基团等，或其药学上可接受的盐，其具有对人类SGLT2的抑制活性，可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及包含它们的制药组合物和中间体。
• Prophylactic and therapeutic agent of diabetes mellitus
  申请人：Maezono Katsumi

  公开号：US20050143424A1

  公开（公告）日：2005-06-30

  The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

  本发明提供了一种糖尿病的预防和治疗剂，包括肾脏葡萄糖重吸收抑制剂和降糖剂的组合。根据本发明，可以改善餐后、餐间和禁食期间的高血糖。更具体地，根据本发明，可以实现糖尿病的治疗效果，这是以往相关艺术中的降糖药物所未曾达到的。
• Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：——

  公开号：US20040053855A1

  公开（公告）日：2004-03-18

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式1所表示的葡萄糖吡喃基氧基苯基苯基衍生物，其中R1代表氢原子或羟基（较低烷基）基团；R2代表较低烷基基团、较低烷氧基基团、较低烷基硫基基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐，具有出色的人类SGLT2抑制活性，并可用作糖尿病、肥胖等的预防或治疗药物及其中间体。
• Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
  申请人：——

  公开号：US20040063170A1

  公开（公告）日：2004-04-01

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein R 1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted (lower alkyl) group, a substituted or unsubstituted (lower alkoxy) group etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents a substituted or unsubstituted (lower alkyl) group, a substituted or unsubstituted (lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及由下式表示的葡萄糖吡喃基氧基苯基苯基衍生物： 其中，R1代表氢原子、羟基、取代或未取代的氨基、氨基甲酰基、取代或未取代的(较低烷基)基团、取代或未取代的(较低烷氧基)基团等；R2代表氢原子或较低烷基基团；R3代表取代或未取代的(较低烷基)基团、取代或未取代的(较低烷氧基)基团、取代或未取代的(较低烷硫基)基团等，或其药学上可接受的盐，其在人类SGLT2中具有抑制活性，并且可用作预防或治疗与高血糖有关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂。本发明还涉及包含上述衍生物的制药组合物及其中间体。